News | January 11, 2026
Pulmocide halts Phase 3 trial of Opelconazole in severe lung infection
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
Subscribe To Our Newsletter & Stay Updated
